Investors Overview Press Releases Events & Presentations Financials Stock Information Corporate Governance FAQ Email Alerts Contact Investors: Press Releases Press Releases News Releases Announcements Press Releases Year None202220212020201920182017 May 12, 2022 AVITA Medical Reports First Quarter 2022 Financial Results May 9, 2022 RECELL® System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology Meeting April 28, 2022 AVITA Medical to Announce First Quarter 2022 Financial Results April 21, 2022 Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors April 4, 2022 RECELL® System Data to be Presented at the American Burn Association Annual Meeting March 23, 2022 RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium March 21, 2022 AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL® System in Soft Tissue Reconstruction March 2, 2022 Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL® System to Hospitals and Health Systems Across the U.S. February 28, 2022 AVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results February 23, 2022 The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company February 23, 2022 AVITA Medical to Present at the Cowen 42nd Annual Health Care Conference February 17, 2022 AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use February 15, 2022 AVITA Medical to Announce Transition Period July 1, 2021 to December 31, 2021 Financial Results February 2, 2022 AVITA Medical to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference January 24, 2022 RECELL® System Data to be Presented at 44th Annual John A. Boswick Burn & Wound Care Symposium January 10, 2022 AVITA Medical Announces Preliminary Unaudited Results for the Quarter ended December 31, 2021 January 6, 2022 AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Soft-Tissue Reconstruction January 6, 2022 AVITA Medical Establishes Proof of Concept for Novel Treatments Using Genetically-Modified Skin Cells
Press Releases Year None202220212020201920182017 May 12, 2022 AVITA Medical Reports First Quarter 2022 Financial Results May 9, 2022 RECELL® System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology Meeting April 28, 2022 AVITA Medical to Announce First Quarter 2022 Financial Results April 21, 2022 Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors April 4, 2022 RECELL® System Data to be Presented at the American Burn Association Annual Meeting March 23, 2022 RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium March 21, 2022 AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL® System in Soft Tissue Reconstruction March 2, 2022 Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL® System to Hospitals and Health Systems Across the U.S. February 28, 2022 AVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results February 23, 2022 The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company February 23, 2022 AVITA Medical to Present at the Cowen 42nd Annual Health Care Conference February 17, 2022 AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use February 15, 2022 AVITA Medical to Announce Transition Period July 1, 2021 to December 31, 2021 Financial Results February 2, 2022 AVITA Medical to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference January 24, 2022 RECELL® System Data to be Presented at 44th Annual John A. Boswick Burn & Wound Care Symposium January 10, 2022 AVITA Medical Announces Preliminary Unaudited Results for the Quarter ended December 31, 2021 January 6, 2022 AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Soft-Tissue Reconstruction January 6, 2022 AVITA Medical Establishes Proof of Concept for Novel Treatments Using Genetically-Modified Skin Cells
May 9, 2022 RECELL® System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology Meeting
March 23, 2022 RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium
March 21, 2022 AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL® System in Soft Tissue Reconstruction
March 2, 2022 Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL® System to Hospitals and Health Systems Across the U.S.
February 28, 2022 AVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results
February 23, 2022 The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company
February 17, 2022 AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use
February 15, 2022 AVITA Medical to Announce Transition Period July 1, 2021 to December 31, 2021 Financial Results
February 2, 2022 AVITA Medical to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
January 24, 2022 RECELL® System Data to be Presented at 44th Annual John A. Boswick Burn & Wound Care Symposium
January 10, 2022 AVITA Medical Announces Preliminary Unaudited Results for the Quarter ended December 31, 2021
January 6, 2022 AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Soft-Tissue Reconstruction
January 6, 2022 AVITA Medical Establishes Proof of Concept for Novel Treatments Using Genetically-Modified Skin Cells